NCT02915744
, Valero, V
In Reply We appreciate the comments from Mo et al regarding the overall survival (OS) of patients with stable brain metastases (BMs) at baseline in the explorat Okines A, et
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain
Dec 1, 2022 · c Placebo, trastuzumab, and capecitabine
2023
1 This number is even higher for patients with triple-negative breast cancer (TNBC), with
Validation of the current study results will be determined in the double-blinded randomised study, HER2CLIMB (ONT-380-206; NCT02614794)
The development of breast cancer (BC) brain metastases (BrM) is a common complication of advanced disease, occurring in up to half of the patients with advanced disease depending on the subtype
Breast cancer brain metastases (BCBM) have been associated with reduced survival and poor morbidity, including
Neratinib and capecitabine for breast cancer brain metastases
Jan 1, 2013 · The occurrence of brain metastases in patients with metastatic breast cancer is becoming increasingly common, probably because of both longer life expectancy and improvements in diagnotic methods compared with before 2000 (the pre-trastuzumab era)
Patients with measurable, progressive, HER2-positive brain metastases (92% after receiving CNS surgery and/or radiotherapy) received neratinib 240 mg orally once per day plus capecitabine 750 mg/m 2 twice per day for 14 days, then 7 days off
Jan 25, 2009 · Preclinical data have demonstrated that ionizing radiation acts synergistically with capecitabine